A compound represented by formula (1-1) or (1-2) or a pharmacologically acceptable salt thereof retains the principal therapeutic effect of sitaxentan and has an improved CYP inhibitory effect: wherein R1 is a halogen atom etc. R2 is a methyl group etc. R3 is a C1-6 alkyl group etc. and M is a group represented by: etc.

To provide a compound retaining the principal therapeutic effect of sitaxentan and having an improved CYP inhibitory effect. A compound represented by formula (1-1) or (1-2), or a pharmacologically acceptable salt thereof: wherein R1 is a halogen atom, etc., R2 is a methyl group, etc., R3 is a C1-6 alkyl group, etc., and M is a group represented by: , etc.

A compound represented by formula (1-1) or (1-2), or a pharmacologically acceptable salt thereof retains the principal therapeutic effect of sitaxentan and has an improved CYP inhibitory effect: wherein R1 is a halogen atom, etc., R2 is a methyl group, etc., R3 is a C1-6 alkyl group, etc., and M is a group represented by: etc.

A compound represented by formula (1-1) or (1-2) or a pharmacologically acceptable salt thereof retains the principal therapeutic effect of sitaxentan and has an improved CYP inhibitory effect: wherein R1 is a halogen atom etc. R2 is a methyl group etc. R3 is a C1-6 alkyl group etc. and M is a group represented by: etc.